Initially developed as a treatment for chronic myeloid leukaemia due to its activity against the fusion protein breakpoint cluster region-Abelson murine leukaemia (BCR-ABL), the structural similarity between ABL and KIT led to pre-clinical and subsequent clinical trials confirming IM activity in GIST (52). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.